24465863 28919642 34952161 28877262 24270242 33556542 22021082 29433982 20887871 29180681 23567651 24267638 31334034 33428941 24839101 24486885 34816484 22302797 23314528 20036196 30046897 26057626 22499677 26940058 25231978 21826257 24434619 3618386 - Search Results

Year	Number of Results
2009	4
2010	7
2011	9
2012	10
2013	10
2014	11
2015	10
2016	9
2017	7
2018	4
2019	2
2020	3
2021	6
2022	7
2023	1

1

Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss.

McFarland NR, Dimant H, Kibuuka L, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer M, Fan Z, Schwarzschild MA, Hirst W, McLean PJ. McFarland NR, et al. PLoS One. 2014 Jan 20;9(1):e86048. doi: 10.1371/journal.pone.0086048. eCollection 2014. PLoS One. 2014. PMID: 24465863 Free PMC article.

2

Membrane Binding of Parkinson's Protein α-Synuclein: Effect of Phosphorylation at Positions 87 and 129 by the S to D Mutation Approach.

Kumar P, Schilderink N, Subramaniam V, Huber M. Kumar P, et al. Isr J Chem. 2017 Jul;57(7-8):762-770. doi: 10.1002/ijch.201600083. Epub 2016 Nov 10. Isr J Chem. 2017. PMID: 28919642 Free PMC article.

3

Animal models of brain-first and body-first Parkinson's disease.

Van Den Berge N, Ulusoy A. Van Den Berge N, et al. Neurobiol Dis. 2022 Feb;163:105599. doi: 10.1016/j.nbd.2021.105599. Epub 2021 Dec 22. Neurobiol Dis. 2022. PMID: 34952161 Free article. Review.

4

The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome.

Park HJ, Ryu D, Parmar M, Giasson BI, McFarland NR. Park HJ, et al. PLoS One. 2017 Sep 6;12(9):e0184262. doi: 10.1371/journal.pone.0184262. eCollection 2017. PLoS One. 2017. PMID: 28877262 Free PMC article.

5

Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.

Wales P, Pinho R, Lázaro DF, Outeiro TF. Wales P, et al. J Parkinsons Dis. 2013;3(4):415-59. doi: 10.3233/JPD-130216. J Parkinsons Dis. 2013. PMID: 24270242 Review.

6

In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129.

Weston LJ, Cook ZT, Stackhouse TL, Sal MK, Schultz BI, Tobias ZJC, Osterberg VR, Brockway NL, Pizano S, Glover G, Weissman TA, Unni VK. Weston LJ, et al. Neurobiol Dis. 2021 May;152:105291. doi: 10.1016/j.nbd.2021.105291. Epub 2021 Feb 5. Neurobiol Dis. 2021. PMID: 33556542 Free article.

7

Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra.

Khodr CE, Pedapati J, Han Y, Bohn MC. Khodr CE, et al. Dev Neurobiol. 2012 Jun;72(6):906-17. doi: 10.1002/dneu.20989. Dev Neurobiol. 2012. PMID: 22021082 Free PMC article.

8

Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice.

Cai W, Feng D, Schwarzschild MA, McLean PJ, Chen X. Cai W, et al. EBioMedicine. 2018 Mar;29:13-22. doi: 10.1016/j.ebiom.2018.01.035. Epub 2018 Jan 31. EBioMedicine. 2018. PMID: 29433982 Free PMC article.

9

Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.

Ulusoy A, Decressac M, Kirik D, Björklund A. Ulusoy A, et al. Prog Brain Res. 2010;184:89-111. doi: 10.1016/S0079-6123(10)84005-1. Prog Brain Res. 2010. PMID: 20887871 Review.

10

Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression.

Fischer DL, Manfredsson FP, Kemp CJ, Cole-Strauss A, Lipton JW, Duffy MF, Polinski NK, Steece-Collier K, Collier TJ, Gombash SE, Buhlinger DJ, Sortwell CE. Fischer DL, et al. Sci Rep. 2017 Nov 27;7(1):16356. doi: 10.1038/s41598-017-16690-x. Sci Rep. 2017. PMID: 29180681 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results